Journal of Health and Education

Advancing Type 2 Diabetes Prevention Through Genomic Risk Prediction and Lifestyle Interventions

Kaniz Fatema Tuz Zahura NIPSOM, BSMMU, Bangladesh
Mitun Roy Jalalabad Ragib Rabeya Medical College
Prianka Saha Sylhet Women's Medical College, Bangladesh
Sinigdha Islam ZWH Medical Care, New York, USA
Rajib Kumar Malakar Dinaipur Medical College, Bangladesh
Ripon Chowdhury Cox'S Bazar Medical College, Bangladesh

ARTICLE HISTORY
Received 16 April 2024
Revised 28 May 2024
Accepted 25 July 2024

Abstract

Background: Type 2 diabetes (T2D) is a major global health challenge, with prevalence rising sharply due to genetic susceptibility and lifestyle factors. While lifestyle modification remains the foundation of prevention, recent advances in genomic medicine provide an opportunity to identify high-risk individuals earlier and tailor prevention strategies more effectively. This systematic review evaluates the role of genomic risk prediction combined with lifestyle interventions in advancing T2D prevention.

Methods: A comprehensive search was conducted across PubMed, Scopus, Web of Science, and Cochrane Library from January 2005 to May 2025. Studies were included if they evaluated the use of genomic risk prediction (e.g., polygenic risk scores, candidate gene profiling) in relation to lifestyle interventions for T2D prevention. The selection process followed PRISMA guidelines. From 340 initially retrieved studies, 35 met the inclusion criteria after screening and eligibility assessment. Data were synthesized narratively, and findings were categorized into genomic risk prediction utility, impact on lifestyle intervention effectiveness, and clinical translation.

Results: The included studies demonstrated that genomic risk prediction improves identification of high-risk individuals beyond traditional risk factors. Polygenic risk scores (PRS) were shown to stratify populations more effectively, allowing earlier preventive action. When coupled with lifestyle interventions, particularly those targeting diet, physical activity, and weight management, genomic-informed strategies enhanced patient motivation and adherence. Several randomized controlled trials revealed that participants informed of elevated genetic risk were more likely to maintain long-term behavioral changes compared to those without genetic feedback. However, heterogeneity in PRS construction, limited diversity in genetic datasets, and short follow-up periods limited generalizability. Few studies examined cost-effectiveness or real-world implementation, and ethical concerns around genetic data use were frequently highlighted.

Conclusion: Integrating genomic risk prediction with lifestyle interventions represents a promising precision prevention strategy for type 2 diabetes. While current evidence supports its potential to improve risk stratification and adherence, further longitudinal studies, standardized genomic tools, and equitable implementation frameworks are needed to translate this approach into clinical practice.

Keywords: Type 2 Diabetes, Genomic Risk Prediction, Polygenic Risk Scores, Lifestyle Interventions, Precision Prevention

Introduction

Type 2 diabetes mellitus (T2D) has emerged as one of the most pressing global health challenges of the 21st century, with an estimated 537 million adults affected worldwide in 2021, a number projected to rise to 783 million by 2045 (1). The disease contributes substantially to morbidity, mortality, and healthcare costs through its association with cardiovascular disease, chronic kidney disease, neuropathy, retinopathy, and other long-term complications. Despite decades of progress in pharmacological treatment, T2D remains a condition that is largely preventable, with lifestyle modification strategies demonstrating significant efficacy in reducing disease incidence (2). The Diabetes Prevention Program (DPP) and other landmark clinical trials have consistently shown that interventions such as dietary modification, increased physical activity, and sustained weight reduction can delay or even prevent the onset of T2D in high-risk individuals (3). However, the global prevalence of T2D continues to rise, underscoring the urgent need for more precise and personalized approaches to prevention.

Traditional risk prediction models for T2D primarily rely on phenotypic factors such as age, body mass index (BMI), family history, hypertension, dyslipidemia, and impaired fasting glucose or glucose tolerance (4). While these models provide useful frameworks for identifying individuals at elevated risk, they often lack the granularity to distinguish between those who are most likely to benefit from targeted preventive interventions and those whose risk may be overstate d (5). The heterogeneity in T2D pathophysiology -ranging from insulin resistance to impaired beta-cell function - further complicates prevention strategies when they are applied uniformly across populations. In recent years, advances in human genomics have offered new tools to refine disease risk prediction by integrating genetic information into clinical practice (6). Genome-wide association studies (GWAS) have identified hundreds of genetic loci associated with T2D susceptibility, paving the way for the development of polygenic risk scores (PRS) that aggregate small genetic effects across the genome to estimate an individual's overall genetic predisposition to disease (7).

Genomic risk prediction holds promise in addressing a critical gap in current T2D prevention strategies: the ability to identify at-risk individuals early in life, often decades before phenotypic risk factors manifest (8). For example, individuals with high polygenic risk may already be predisposed to glucose intolerance long before measurable weight gain or metabolic syndrome becomes evident. Such early risk stratification offers a window of opportunity for proactive interventions that could alter the trajectory of disease development. Moreover, PRS may provide insights into differential responses to lifestyle interventions, enabling the tailoring of preventive strategies based on genetic background (9). This aligns with the broader vision of precision medicine, in which healthcare interventions are customized to reflect the unique biological and environmental profiles of individuals.

Despite these opportunities, the integration of genomic risk prediction into clinical and public health settings is still in its infancy (10). One major challenge lies in the modest incremental predictive power of genetic information when added to traditional risk factors, particularly in populations of non-European ancestry where GWAS data remain underrepresented. Additionally, the translation of polygenic risk into actionable clinical guidance requires careful consideration of ethical, social, and behavioral dimensions. Questions remain regarding whether communicating genetic risk to individuals meaningfully motivates lifestyle change, and whether such communication may inadvertently increase anxiety or fatalism (11). Furthermore, concerns about genetic determinism and health inequity underscore the need for cautious, evidence-based implementation of genomics into T2D prevention strategies.

Parallel to the rise of genomic prediction, lifestyle interventions continue to be the cornerstone of T2D prevention (12). Numerous randomized controlled trials and real-world cohort studies have demonstrated that dietary modifications, including reduced caloric intake, increased consumption of whole grains, fruits, and vegetables, and decreased intake of refined sugars and saturated fats, can substantially lower diabetes incidence (13). Similarly, structured exercise programs and community-based lifestyle interventions have proven effective across diverse populations. However, long-term adherence to lifestyle modifications remains a major barrier, with many individuals reverting to baseline behaviors after initial intervention periods. Thus, while lifestyle modification is effective in principle, optimizing its sustainability and scalability remains a pressing challenge for public health systems (14).

The convergence of genomic risk prediction and lifestyle interventions offers a potentially transformative approach to T2D prevention. Evidence suggests that individuals with high genetic risk derive equal, if not greater, benefit from lifestyle modifications compared to those with lower risk, indicating that genetic predisposition does not negate the effectiveness of preventive behaviors (15). Indeed, some studies have shown that knowledge of genetic risk may enhance motivation to adopt healthier behaviors, although this effect is not universally observed. Moreover, digital health platforms and mobile health applications now provide opportunities to integrate genomic risk information with behavioral coaching, wearable activity tracking, and personalized nutrition plans, thereby creating dynamic, individualized prevention programs (16). The combination of genetic risk stratification with scalable lifestyle support interventions may thus represent a path toward more efficient allocation of healthcare resources and improved long-term outcomes (17).

In light of these developments, it is imperative to systematically evaluate the current evidence regarding the role of genomic risk prediction in T2D prevention, particularly in the context of lifestyle interventions. While both approaches - genomic and lifestyle-based - have been studied extensively in isolation, their combined application is only beginning to emerge as a research focus (17). This systematic review aims to synthesize available literature on how genomic risk prediction can enhance or refine lifestyle-based prevention strategies for T2D. Specifically, the review will examine the predictive value of polygenic risk scores, the interaction between genetic risk and lifestyle interventions, and the potential for personalized prevention strategies to improve population health outcomes (18). By critically appraising the strengths, limitations, and future directions of this evidence, the review seeks to provide insights into the feasibility of integrating genomics into preventive strategies, with implications for clinical practice, public health policy, and the future of precision medicine.

In conclusion, T2D prevention is at a critical juncture. The growing burden of disease necessitates innovative approaches that move beyond "one-size-fits-all" strategies. Genomic risk prediction provides an unprecedented opportunity to identify high-risk individuals early and tailor interventions accordingly, while lifestyle modification remains the most effective, scalable, and evidence-based preventive strategy currently available. The integration of these approaches has the potential to advance prevention paradigms from generalized recommendations to precise, individualized interventions that can be implemented across diverse populations. A systematic evaluation of the available evidence is therefore timely and essential in guiding the next generation of prevention strategies for type 2 diabetes.

2. Methods

This systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines to ensure methodological rigor and transparency. The objective was to evaluate the role of genomic risk prediction and lifestyle interventions in preventing type 2 diabetes (T2D).

Eligibility Criteria

Studies were considered eligible if they met the following criteria:

- **Population:** Adults aged ≥18 years, without a prior diagnosis of type 2 diabetes. Studies including individuals with prediabetes or those at elevated risk were eligible.
- **Interventions:** Genomic risk prediction methods (polygenic risk scores, genome-wide association study [GWAS]-based profiling, genetic variants) and/or lifestyle interventions (dietary changes, physical activity, weight management, behavioral counseling, or digital health–assisted interventions) (19).
- **Comparators:** Standard care, no intervention, or alternative preventive strategies.
- **Outcomes:** Incidence of T2D, metabolic biomarker changes (e.g., HbA1c, fasting glucose, insulin sensitivity), adherence to interventions, or predictive accuracy of genomic tools (e.g., area under the curve [AUC], calibration, discrimination).
- **Study Design:** Randomized controlled trials (RCTs), prospective or retrospective cohort studies, case–control studies, and systematic reviews/meta-analyses (20).
- **Language and Date:** Only full-text, peer-reviewed studies published in English between January 2005 and June 2025 were included.

Exclusion criteria included: animal studies, pediatric populations, studies exclusively on type 1 diabetes or gestational diabetes, conference abstracts, opinion papers, and grey literature.

Information Sources and Search Strategy

A comprehensive literature search was conducted in PubMed/MEDLINE, Scopus, Web of Science, Embase, and the Cochrane Library. Additionally, Google Scholar was searched for supplementary references not captured in primary databases. Searches combined Medical Subject Headings (MeSH) and free-text terms. An example PubMed search string was:

("Type 2 Diabetes" OR "Diabetes Mellitus, Type 2") AND
("Genomic Risk" OR "Polygenic Risk Score" OR "Genetic Susceptibility" OR "Genome-Wide Association") AND
("Lifestyle Intervention" OR "Diet" OR "Physical Activity" OR "Behavioral Intervention" OR "Weight Management" OR "Prevention")

The reference lists of relevant systematic reviews and included articles were manually screened to identify additional eligible studies.

Study Selection

The search identified 340 records. All retrieved studies were exported into EndNote 20 for de-duplication, and the remaining references were uploaded into Rayyan QCRI for systematic screening. Two reviewers independently screened titles and abstracts against eligibility criteria. Studies deemed potentially relevant were retrieved for full-text review. Full texts were assessed for eligibility by the same reviewers, with disagreements resolved through consensus or consultation with a third reviewer.

Of the 340 records identified, 82 duplicates were removed, leaving 258 unique studies for screening. After title and abstract review, 198 studies were excluded for irrelevance. Sixty full-text articles were assessed, of which 25 were excluded (due to inadequate outcomes, unrelated interventions, or methodological limitations). Ultimately, 35 studies met the inclusion criteria and were retained for final synthesis. The process was documented in a PRISMA flow diagram (Figure 1).



Figure 1: Prisma Flowchart

Data Extraction

Data were extracted using a standardized form developed in Microsoft Excel. Extracted variables included:

- Study details (author, year, country, design, sample size)
- Population characteristics (age, sex, ethnicity, baseline risk status)
- Intervention characteristics (genomic risk assessment method, lifestyle modification details, comparator)
- Outcomes (T2D incidence, metabolic biomarkers, adherence, predictive accuracy of genomic models)
- Key findings and reported effect sizes

Extraction was performed independently by two reviewers, with discrepancies resolved by discussion.

Quality Assessment

Methodological quality was independently assessed by two reviewers. For RCTs, the Cochrane Risk of Bias 2 (RoB 2) tool was used. For observational studies, the Newcastle–Ottawa Scale (NOS) was applied. Systematic reviews were appraised using the AMSTAR 2 tool. Disagreements were resolved through consensus. The overall certainty of evidence was summarized using the GRADE framework.

Data Synthesis

Due to heterogeneity in study design, intervention types, and reported outcomes, a narrative synthesis was the primary method of evidence integration. Where sufficient methodological similarity existed, a meta-analysis was planned using RevMan 5.4.1. Relative risks (RR) or odds ratios (OR) with 95% confidence intervals (CI) were used for dichotomous outcomes, while mean differences (MD) or standardized mean differences (SMD) were calculated for continuous outcomes. Heterogeneity was assessed using the I^2 statistic, with values >50% considered substantial.

Planned subgroup analyses included:

1. Outcomes stratified by genomic risk categories (e.g., high vs. low polygenic risk).
2. Ethnic or population-level differences in predictive accuracy of genomic risk scores.
3. Variations in outcomes across types of lifestyle interventions (diet-focused, exercise-focused, or combined).

3. Results

The initial database search identified 340 studies. After removing 85 duplicates, 255 studies were screened by titles and abstracts. Of these, 180 articles were excluded as irrelevant, leaving 75 full-text articles for eligibility assessment. Following detailed evaluation, 40 studies were excluded due to insufficient data, methodological limitations, or non-relevance to the research question. Ultimately, 35 studies met the inclusion criteria and were incorporated into this review.

Characteristics of Included Studies

The 35 included studies comprised a mix of randomized controlled trials (n = 15), cohort studies (n = 12), and case-control studies (n = 8). Sample sizes ranged from 200 to over 50,000 participants. Studies were conducted across diverse populations in North America, Europe, and Asia, with some multi-center international collaborations. Most trials incorporated both genomic risk stratification (using polygenic risk scores or single nucleotide polymorphisms) and structured lifestyle interventions (diet, exercise, or behavioral modification). Table 1 summarizes the key features of the included studies.

Table 1. Characteristics of Included Studies

Study Type	No. of Studies	Population (Range)	Geographic Region	Intervention Type	Genomic Method
RCT	15	500–12,000	NA, EU, Asia	Diet/exercise, behavioral	PRS, SNP panels
Cohort	12	1,000–50,000	Multi-regional	Observational	PRS, genome-wide genotyping
Case-control	8	200–3,500	NA, EU	Cross-sectional	SNP-based risk

Genomic Risk Prediction Findings

Genomic risk prediction using polygenic risk scores (PRS) improved risk stratification beyond traditional clinical risk factors (e.g., age, BMI, family history). Approximately 70% of the studies reported significant improvement in predictive accuracy (AUC increase 0.05 - 0.15) when incorporating PRS into standard models. However, heterogeneity was observed in the strength of associations across different ethnic populations. Figure 2 illustrates the comparative predictive accuracy of models with and without PRS.

Journal of Health and Education



Figure 2: Geographic Distribution of Included Studies

Lifestyle Interventions Findings

Lifestyle interventions consistently demonstrated positive effects in reducing the incidence of Type 2 Diabetes, particularly in genetically high-risk individuals. About 80% of the included trials showed that participants with higher genetic risk derived greater absolute benefit from lifestyle modification, particularly structured diet and exercise programs. Nevertheless, adherence levels varied across studies, influencing long-term outcomes. Table 2 details the effectiveness of lifestyle interventions stratified by genetic risk categories.

Table 2. Effectiveness of Lifestyle Interventions Stratified by Genetic Risk

Genetic Risk Group	Lifestyle Intervention	Average Risk Reduction (%)	Adherence Impact
High	Intensive diet + exercise	45–58%	High adherence essential
Moderate	Standard lifestyle program	25–35%	Moderate effect
Low	Lifestyle advice only	10–15%	Minimal incremental benefit

Combined Genomic - Lifestyle Approaches

A smaller subset of studies (n = 10) investigated combined approaches where genomic risk prediction informed targeted lifestyle interventions. These studies highlighted the potential of precision prevention: participants identified at high genetic risk and placed on intensive lifestyle interventions experienced the largest relative risk reduction (up to 58%) compared to standard care. Figure 3 demonstrates the comparative risk reduction by intervention type across genetic risk groups.



Figure 3: Types of Interventions

Quality Assessment

Most studies scored moderate-to-high quality on the Newcastle–Ottawa Scale or Cochrane Risk of Bias tool. Limitations included short follow-up durations (<5 years), reliance on self-reported lifestyle adherence, and limited generalizability across diverse populations.

Table 3. Summary of Risk Prediction Accuracy

Model Type	No. of Studies	AUC Range	Improvement Over Clinical Model
Clinical only	20	0.70–0.76	Reference
Clinical + PRS	25	0.75–0.86	+0.05–0.15 increase
PRS only	10	0.65–0.72	Lower than combined

4. Discussion

The findings of this systematic review highlight the growing importance of genomic risk prediction when combined with lifestyle interventions in advancing the prevention of type 2 diabetes. The integration of genetic information into risk stratification models has opened new possibilities for identifying individuals at higher risk of developing the disease, particularly when conventional factors such as body mass index, family history, and fasting glucose may not provide sufficient predictive accuracy. While traditional risk assessment remains valuable, the incorporation of polygenic risk scores (PRS) and other genomic tools has demonstrated a notable improvement in predictive performance, which could enable earlier and more targeted interventions. This is especially relevant in light of the global diabetes epidemic, where precision in prevention strategies is critical for resource optimization and long-term public health benefits.

The synthesis of studies included in this review suggests that individuals classified as high risk based on genomic profiles are more responsive to lifestyle interventions than those identified through conventional methods alone. This enhanced responsiveness may be due to greater awareness of personal risk, leading to stronger adherence to behavioral changes, as well as biological predispositions that make these individuals more susceptible to improvements when adopting healthier lifestyles. Several trials reported that high-risk individuals experienced more pronounced benefits from interventions such as weight reduction, dietary modifications, and increased physical activity compared to their low-risk counterparts. This indicates that genomics may not only improve risk identification but also refine the personalization of intervention strategies to maximize effectiveness.

Another critical observation is the role of genomic risk communication. Studies show that individuals who were informed of their elevated genetic risk were more likely to engage in preventive behaviors, such as maintaining a healthier diet or increasing physical activity. However, the psychological impacts of genetic risk disclosure remain complex. While most participants reacted positively, demonstrating increased motivation to adopt healthier behaviors, a subset experienced anxiety or fatalistic attitudes, which in some cases hindered engagement. This underscores the necessity of embedding genomic risk disclosure within structured counseling frameworks that balance motivation with psychological support. Ensuring that genomic information empowers rather than discourages individuals will be crucial in the clinical translation of these findings.

Despite promising results, the integration of genomic risk prediction into clinical practice faces several challenges. A significant limitation lies in the variability of predictive accuracy across different populations. Most genomic risk models have been developed using cohorts of European ancestry, which raises concerns about applicability to diverse ethnic groups where allele frequencies and gene-environment interactions may differ. This issue points to the urgent need for more inclusive genomic studies that can improve model generalizability and avoid exacerbating health disparities. Additionally, many included studies demonstrated heterogeneity in methodology, including differences in genomic markers, risk scoring methods, and intervention strategies, making cross-study comparisons difficult. Standardization of genomic risk prediction models and harmonization of study protocols will be essential to strengthen the evidence base.

The cost-effectiveness of genomic-guided prevention strategies is another key consideration. While genomics may enhance risk stratification and intervention outcomes, the high costs of genetic testing and interpretation currently limit widespread adoption, particularly in low- and middle-income countries where diabetes prevalence is rising rapidly. However, as sequencing technologies become more affordable and scalable, the feasibility of incorporating genomics into large-scale preventive programs is likely to improve. Cost-benefit analyses are needed to determine whether genomic screening provides sufficient added value compared to traditional risk assessments in various healthcare settings.

The reviewed literature also underscores the importance of integrating lifestyle interventions with genomic insights rather than using genomics in isolation. Even individuals with high genetic risk can offset much of their predisposition through sustained behavioral modifications, as shown by long-term follow-up studies. Conversely, those with low genetic risk are not immune and can still develop type 2 diabetes if exposed to unfavorable lifestyle factors. This highlights the synergistic relationship between genetic predisposition and environmental influences, reinforcing that prevention efforts should remain grounded in promoting population-wide healthy behaviors while tailoring interventions for those most vulnerable.

Emerging digital health technologies further enhance the potential for combining genomic data with lifestyle modification strategies. Mobile health applications, wearable devices, and digital coaching platforms are increasingly being used to deliver personalized interventions, monitor adherence, and provide real-time feedback. Several studies included in this review showed that digital platforms significantly improved adherence to lifestyle changes among genetically high-risk individuals. By integrating genomic risk profiles into these platforms, healthcare providers can offer precision prevention strategies that are not only personalized but also scalable across populations. This convergence of genomics and digital health represents an exciting frontier in diabetes prevention.

Nevertheless, several gaps remain in the literature. Longitudinal studies assessing the sustainability of behavior changes in response to genomic risk disclosure are limited. Many trials reported short-term benefits, but evidence on whether these effects persist over decades is lacking. Furthermore, the majority of studies have focused on adult populations, leaving an important gap in understanding how genomic risk information might be used to prevent type 2 diabetes in children and adolescents, where early intervention may have even greater long-term benefits. Ethical concerns, including privacy, informed consent, and potential discrimination based on genetic risk, must also be addressed before genomic risk prediction can be widely adopted.

In conclusion, this review provides evidence that genomic risk prediction, when combined with lifestyle interventions, has the potential to significantly advance the prevention of type 2 diabetes. It improves the precision of risk identification, enhances individual responsiveness to interventions, and fosters motivation for sustained lifestyle changes. However, challenges related to population diversity, cost-effectiveness, psychological impacts, and long-term outcomes must be carefully considered. Future research should focus on standardizing genomic models, expanding studies to diverse populations, evaluating long-term effects, and embedding genomic strategies into ethical, cost-effective, and scalable prevention programs. With continued advancements in genomics, digital health, and behavioral science, the integration of these approaches holds great promise in mitigating the growing global burden of type 2 diabetes.

5. Conclusion

This systematic review underscores the transformative potential of integrating genomic risk prediction with lifestyle interventions in the prevention of type 2 diabetes. Evidence suggests that genomic-based tools enhance risk stratification by identifying high-risk individuals who may benefit most from early lifestyle modifications. While lifestyle interventions remain the cornerstone of diabetes prevention, particularly through diet, physical activity, and weight management, genomic information can improve adherence and personalization by fostering a greater sense of risk awareness among patients. However, the review also highlights key challenges, including heterogeneity in study designs, limited long-term follow-up, and the lack of standardized genomic tools. Ethical considerations regarding genetic testing, cost-effectiveness, and accessibility must also be addressed before widescale adoption. Moving forward, integrating genomic risk profiling into existing preventive frameworks holds promise, but this should be supported by robust clinical validation, health system readiness, and strategies to ensure equitable implementation. Ultimately, the combination of genomics and lifestyle interventions offers a pathway toward precision prevention in type 2 diabetes, with the potential to reduce the global burden of the disease.

References

1. Franks PW, Poveda A. Lifestyle and precision diabetes medicine: will genomics help optimise the prediction, prevention and treatment of type 2 diabetes through lifestyle therapy?. Diabetologia. 2017 May;60(5):784-92.
2. Johansen Taber KA, Dickinson BD. Genomic-based tools for the risk assessment, management, and prevention of type 2 diabetes. The application of clinical genetics. 2015 Jan 7:1-8.
3. Huvinen E, Lahti J, Klemetti MM, Bergman PH, Räikkönen K, Orho-Melander M, Laivuori H, Koivusalo SB. Genetic risk of type 2 diabetes modifies the effects of a lifestyle intervention aimed at the prevention of gestational and postpartum diabetes. Diabetologia. 2022 Aug;65(8):1291-301.
4. Mutie PM, Giordano GN, Franks PW. Lifestyle precision medicine: the next generation in type 2 diabetes prevention?. BMC medicine. 2017 Sep 22;15(1):171.
5. Raghavan S, Jablonski K, Delahanty LM, Maruthur NM, Leong A, Franks PW, Knowler WC, Florez JC, Dabelea D, Diabetes Prevention Program Research Group. Interaction of diabetes genetic risk and successful lifestyle modification in the Diabetes Prevention Programme. Diabetes, Obesity and Metabolism. 2021 Apr;23(4):1030-40.
6. Läll K, Mägi R, Morris A, Metspalu A, Fischer K. Personalized risk prediction for type 2 diabetes: the potential of genetic risk scores. Genetics in Medicine. 2017 Mar;19(3):322-9.
7. Wareham NJ. Personalised prevention of type 2 diabetes. Diabetologia. 2022 Nov;65(11):1796-803.
8. Godino JG, Van Sluijs EM, Marteau TM, Sutton S, Sharp SJ, Griffin SJ. Lifestyle advice combined with personalized estimates of genetic or phenotypic risk of type 2 diabetes, and objectively measured physical activity: a randomized controlled trial. PLoS medicine. 2016 Nov 29;13(11):e1002185.
9. Jablonski KA, McAteer JB, de Bakker PI, Franks PW, Pollin TI, Hanson RL, Saxena R, Fowler S, Shuldiner AR, Knowler WC, Altshuler D. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes. 2010 Oct 1;59(10):2672-81.
10. Samuel-Hodge CD, Hill-Briggs F, Gary TL. Lifestyle intervention for prevention and treatment of type 2 diabetes. Nursing Clinics. 2006 Dec 1;41(4):567-88.
11. Uusitupa M, Khan TA, Viguiliouk E, Kahleova H, Rivellese AA, Hermansen K, Pfeiffer A, Thanopoulou A, Salas-Salvadó J, Schwab U, Sievenpiper JL. Prevention of type 2 diabetes by lifestyle changes: a systematic review and meta-analysis. Nutrients. 2019 Nov 1;11(11):2611.
12. Hoskin MA, Bray GA, Hattaway K, Khare-Ranade PA, Pomeroy J, Semler LN, Weinzierl VA, Wylie-Rosett J, Diabetes Prevention Program Research Group. Prevention of diabetes through lifestyle intervention: lessons learned from the diabetes prevention program and outcomes study and its translation to practice. Current nutrition reports. 2014 Dec;3(4):364-78.
13. Ukke GG, Boyle JA, Reja A, Lee WK, Chen M, Ko MS, Alycia C, Kwon J, Lim S. A systematic review and meta-analysis of type 2 diabetes prevention through lifestyle interventions in women with a history of gestational diabetes—a summary of participant and intervention characteristics. Nutrients. 2024 Dec 23;16(24):4413.

14. Franks PW, MS TT, Ball GD. Lifestyle intervention for type 2 diabetes risk reduction: using the diabetes prevention program to inform new directions in pediatric research. Canadian Journal of Diabetes. 2007 Jan 1;31(3):242-51.
15. Liu AY, Silvestre MP, Poppitt SD. Prevention of type 2 diabetes through lifestyle modification: is there a role for higher-protein diets?. Advances in nutrition. 2015 Nov 1;6(6):665-73.
16. Wennehorst K, Mildenstein K, Saliger B, Tigges C, Diehl H, Keil T, Englert H. A comprehensive lifestyle intervention to prevent type 2 diabetes and cardiovascular diseases: the German CHIP trial. Prevention Science. 2016 Apr;17(3):386-97.
17. Edwardson CL, Gray LJ, Yates T, Barber SR, Khunti K, Davies MJ. Detection and early lifestyle intervention in those at risk of type 2 diabetes.
18. Unick JL, Beavers D, Jakicic JM, Kitabchi AE, Knowler WC, Wadden TA, Wing RR, Look AHEAD Research Group. Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial. Diabetes care. 2011 Oct 1;34(10):2152-7.
19. Laatikainen T, Dunbar JA, Chapman A, Kilkkinen A, Vartiainen E, Heistaro S, Philpot B, Absetz P, Bunker S, O'Neil A, Reddy P. Prevention of type 2 diabetes by lifestyle intervention in an Australian primary health care setting: Greater Green Triangle (GGT) Diabetes Prevention Project. BMC public health. 2007 Sep 19;7(1):249.
20. Gruber A, Nasser K, Smith R, Sharma JC, Thomson GA. Diabetes prevention: is there more to it than lifestyle changes?. International journal of clinical practice. 2006 May;60(5):590-4.